Modernizing the Accelerated Approval Pathway Act of 2022
Bill journey · stage 2 of 5
Under committee review
What it doesSummary introduced in senate (Jun 22, 2022)
Modernizing the Accelerated Approval Pathway Act of 2022
This bill modifies provisions relating to the accelerated approval of drugs for serious or life-threatening diseases or conditions, including by requiring the Food and Drug Administration (FDA) to publish its reasons when it determines a postapproval study to be unnecessary. The bill also establishes a pilot program and an FDA council to support the development of drugs for rare diseases and ensure the appropriate use of the accelerated approval pathway, respectively.
What just happenedJun 22, 2022
Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S3077-3078)
Who’s behind it
- Introduced in SenateJun 22, 2022
- Jun 22, 2022IntroReferral
Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S3077-3078)
Health, Education, Labor, and Pensions Committee - Jun 22, 2022IntroReferral10000
Introduced in Senate